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The	  Big	  Picture	  
•  Over	  the	  course	  of	  my	  en1re	  career,	  I	  want	  to	  
help	  understand	  the	  pathophysiology	  of	  severe	  
mental	  disorders,	  including	  such	  things	  as	  
developmental	  delay,	  mental	  retarda1on,	  
psycho1c	  disorders	  (schizophrenia,	  bipolar,	  
schizoaffec1ve),	  ToureMe	  Syndrome	  and	  
obsessive	  compulsive	  disorder.	  
•  I	  expect	  this	  to	  uncover	  new	  biology	  along	  the	  
way.	  
Most	  recent	  analysis	  in	  Europe	  showed	  that	  brain	  disorders	  cost	  almost	  US
$1	  trillion	  year	  per	  year,	  more	  than	  cancer,	  cardiovascular	  disease	  and	  
diabetes	  combined.	  
	  







Other-­‐	  brain	  tumor,	  child/adolescent	  developmental	  disorders	  (au'sm,	  
ADHD,	  'cs,	  etc…),	  ea1ng	  disorders,	  epilepsy,	  mental	  retarda'on,	  mul1ple	  
sclerosis,	  neuromuscular	  disorders,	  Parkinson’s,	  personality	  disorders,	  sleep	  
disorders,	  somatoform	  disorder,	  stroke	  and	  trauma1c	  brain	  injury.	  
	  
*	  Cost	  of	  disorders	  of	  the	  brain	  in	  Europe	  2010.	  
Gustavsson	  A,	  et	  al.	  
Eur	  Neuropsychopharmacol.	  2011	  Oct;21(10):718-­‐779.	  Epub	  2011	  Sep	  15.	  
	  
	  
The	  toll	  with	  Brain	  Disorders	  is	  tremendous.	  
Science.	  1976	  Apr	  9;192(4235):105-­‐11.	  
“scien1fic	  advance	  requires	  far	  more	  work	  than	  that	  reported	  by	  the	  
discoverer	  or	  by	  those	  who	  wrote	  key	  ar1cles	  essen1al	  for	  his	  
discovery….	  scien1sts	  earlier	  and	  later	  than	  the	  discoverer	  have	  always	  
been	  essen1al	  to	  each	  discovery	  and	  its	  full	  development.”	  
The	  Story	  began	  for	  me	  at	  least	  by	  1993….	  
	  
when	  I	  joined	  the	  lab	  of	  Don	  St.Germain	  to	  study	  
the	  role	  of	  thyroid	  hormone	  in	  cre'nism,	  which	  is	  
caused	  by	  lack	  of	  iodine	  during	  maternal	  
pregnancy,	  so	  this	  is	  an	  environmentally	  triggered	  
disease.	  
Slater	  SD	  (2010).	  The	  discovery	  of	  thyroid	  replacement	  therapy.	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Thyroid	  Hormone	  and	  Deiodina1on	  
Pathways	  
Endocrinology.	  1999	  Jan;140(1):124-­‐30.	  
J	  Clin	  Invest.	  2006	  Feb;116(2):476-­‐84.	  	  
1996-­‐97	  
•  In	  Cambridge,	  England	  at	  Christ’s	  College,	  
worked	  with	  Mar1n	  Evans	  on	  mouse	  
knockouts*	  and	  models	  of	  human	  disease.	  
•  Met	  Alexander	  Bearn,	  a	  dis1nguished	  human	  
gene1cist	  who	  happened	  to	  be	  a	  fellow	  in	  
residence	  at	  the	  1me.	  He	  wrote	  the	  defini1ve	  
biography	  of	  Archibald	  Garrod.	  
•  At	  that	  1me,	  I	  formalized	  my	  goal	  to	  study	  
human	  gene1cs	  long-­‐term.	  
*Gilmour,	  D.	  T.,	  Lyon,	  G.	  J.,	  ….,	  Evans,	  M.	  J.,	  and	  Colledge,	  W.	  H.	  (1998).	  Mice	  deficient	  for	  
the	  secreted	  glycoprotein	  SPARC/osteonec1n/BM40	  develop	  normally	  but	  show	  severe	  
age-­‐onset	  cataract	  forma1on	  and	  disrup1on	  of	  the	  lens.	  Embo	  J	  17(7):	  1860-­‐70.	  	  	  
“Garrod	  was	  more	  of	  a	  scien1st	  than	  a	  physician.	  His	  bedside	  manner	  was	  said	  
to	  be	  limited	  to	  his	  interest	  in	  his	  pa1ents'	  urine	  samples.”	  
	   	   	   	   	  From	  hMp://www.dnaob.org/13/bio.html	  	  
What	  will	  it	  take	  for	  me	  to	  study	  human	  gene'cs	  
and	  certain	  diseases	  in	  detail	  over	  my	  en're	  
career?	  
“The	  M.D.	  does	  not	  make	  you	  a	  physician,	  
but	  it	  prepares	  you	  to	  become	  one.	  
	  
The	  Ph.D.	  does	  not	  make	  you	  a	  scien1st,	  
but	  it	  prepares	  you	  to	  become	  one.”	  
	  
-­‐Olaf	  Andersen,	  M.D.	  
Director	  of	  Cornell/Rockefeller/Sloan-­‐KeMering	  	  
M.D./Ph.D.	  program	  
	  
M.D.	  Ph.D.	  training	  1997-­‐2004	  
•  Much	  learning	  of	  human	  physiology,	  anatomy	  
and	  disease	  at	  Weill	  Cornell	  Medical	  College.	  
	  
•  Ph.D.	  in	  bacterial	  gene1cs	  and	  chemical	  
biology	  with	  Tom	  Muir	  at	  Rockefeller	  and	  
Richard	  Novick	  at	  NYU.	  
Bacterial	  communica1on	  via	  small	  molecules	  







Lactones (AHL’s) =  
R = (CH2)nCH3, 
CO(CH2)nCH3 
Autoinducing 
Peptides (AIP’s) =  
~6-10 amino acid peptides 
Modifications include 
geranylation, thiolactone 
formation (cyclization)  
Lyon, G. & Muir, T.W., Chem. Biol. 2004	






















Virulence	  in	  Staphylococci	  is	  Controlled	  by	  a	  
Global	  Regulon,	  agr	  
Lyon,	  G.J.,	  and	  Novick,	  R.P.	  Pep%des,	  2004	  
Showing	  Compe''ve	  Antagonism	  at	  RHK	  	  










  1. AIPs Bind Competitively to the AgrC Sensor Domain 
   Use of sensor/kinase chimeras localize the site of AIP binding; Lyon et al, JBC, 2002 
 "
Wright et al, PNAS, 2004	











AIP-1 & AIP-IV differ by 1 residue 
YSTCDFIM 
YSTCYFIM 
Use of sensor-domain chimeras allow the  
major binding determinant for group I & 
IV to be further refined 






































































































































































Becoming	  a	  child,	  adolescent	  and	  adult	  
psychiatrist	  through	  clinical	  residency	  and	  
prac1ce.	  
	  	  
Becoming	  a	  scien1st	  through	  focusing	  on	  the	  
gene1c	  basis	  of	  neuropsychiatric	  diseases.	  
	  

I	  moved	  to	  Utah	  in	  July	  2009	  to	  find	  at	  least	  
one	  new	  human	  disease,	  thus	  revealing	  new	  
biology.	  
	  
  July	  2009-­‐December	  2009:	  A[ended	  weekly	  
gene'cs	  case	  conference	  in	  which	  10-­‐30	  gene'c	  
cases	  are	  presented	  weekly,	  led	  by	  Dr.	  Alan	  Rope	  
and	  a[ended	  by	  Drs.	  John	  Carey	  and	  John	  Opitz.	  
	  
  There	  are	  indeed	  MANY	  idiopathic	  disorders	  not	  
described	  in	  the	  literature,	  many	  of	  which	  have	  
neuropsychiatric	  manifesta'ons.	  I	  thought	  about	  
hundreds	  of	  such	  cases,	  looking	  for	  the	  ideal	  first	  
family	  to	  sequence.	  
Discovering	  a	  new	  syndrome	  and	  its	  
gene1c	  basis.	  
Family	  now	  in	  October	  2011,	  with	  five	  muta'on-­‐








2 +/ 3 +/+ 4 mt/ 
3  +/mt 
5 7 mt/ 
4 5 +/mt 6 7 +/+ 8 +/ 
SB 
6 mt/ 
An	  unrelated	  second	  family	  was	  also	  
iden1fied,	  due	  to	  sharing	  the	  same	  
genotype,	  i.e.	  the	  same	  muta1on.	  
II-1 III-2 
Contributed	  by	  Les	  Biesecker	  and	  colleagues	  at	  NIH	  
Tentative name: Ogden Syndrome, in honor of where 
the first family lives, in Ogden, Utah 
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
 We	  performed	  X-­‐chromosome	  exon	  capture	  
with	  Agilent,	  followed	  by	  Next	  Gen	  
Sequencing	  with	  Illumina.	  
 We	  analyzed	  the	  data	  with	  ANNOVAR	  and	  
VAAST	  (Variant	  Annota'on,	  Analysis	  and	  
Search	  Tool).	  New	  computa'onal	  tools	  for	  
iden'fying	  disease-­‐causing	  muta'ons	  by	  
individual	  genome	  sequencing.	  	  
	  
Yandell,	  M.	  et	  al.	  2011.	  “A	  probabilis1c	  disease-­‐gene	  finder	  for	  personal	  
genomes.”	  Genome	  Res.	  21	  (2011).	  doi:10.1101/gr.123158.111.	  	  	  
	  
Wang,	  K.,	  Li,	  M.,	  and	  Hakonarson,	  H.	  (2010).	  ANNOVAR:	  func1onal	  annota1on	  





VAAST	  integrates	  AAS	  &	  Variant	  frequencies	  
in	  a	  single	  probabilis'c	  framework	  	  
 
•   non-coding variants scored using allele frequency differences 
•  ni : frequency of variant type among all variants observed in 
Background and Target genomes 
 
•  ai: frequency of variant type among disease causing mutations in 
OMIM 
•  This approach means that every variant can be scored, non-synonymous,   
  synonymous, coding, and non-coding. Phylogenetic conservation not     













This is the mutation we found… one nucleotide change 
out of 6 billion nucleotides in a diploid genome… 
 Present	  in	  two	  unrelated	  families	  with	  very	  similar	  
phenotype	  of	  affected	  boys.	  
 Blinded	  Sanger	  sequencing	  showed	  perfect	  segrega'on	  of	  
the	  muta'on	  with	  the	  disease.	  Muta'on	  present	  in	  
Proband,	  Carrier	  Mother,	  Carrier	  Grandmother	  and	  other	  
carrier	  mothers.	  Absent	  in	  unaffected	  brother	  and	  
unaffected	  uncle.	  
 Also	  present	  in	  DNA	  from	  formalin-­‐fixed	  paraffin-­‐
embedded	  'ssue	  from	  two	  other	  deceased	  affected	  boys,	  
found	  in	  pathology	  department,	  saved	  in	  one	  case	  for	  30	  
years.	  
 Muta'on	  NOT	  present	  in	  ~6000	  exomes	  or	  genomes	  
sequenced	  at	  BGI,	  CHOP	  and	  Utah	  for	  other	  projects.	  
Proving Causality of the mutation 
 
The mutation is a missense resulting in 
Serine to Proline change in Naa10p 
 
 - Ser 37 is conserved from yeast to human 
 - Ser37Pro is predicted to affect functionality 
  (SIFT and other prediction programs) 
    - Structural modelling of hNaa10p wt (cyan) and 








The	  muta'on	  disrupts	  the	  N-­‐terminal	  
acetyla'on	  machinery	  (NatA)	  in	  
human	  cells.	  	  
Slide	  courtesy	  of	  Thomas	  Arnesen	  
NAT	  ac'vity	  of	  recombinant	  hNaa10p	  
WT	  or	  p.Ser37Pro	  towards	  synthe'c	  
N-­‐terminal	  pep'des	  	  
	  hNaa10p-­‐S37P	  is	  func'onally	  
impaired	  in	  vivo	  using	  a	  yeast	  model.	  
	  
Unpublished	  data,	  do	  not	  further	  distribute.	  
Big	  Ques1on	  though:	  
 
Simulated	  structure	  of	  S37P	  mutant	  	  
?	  
Open	  ques'on:	  
Func1on	  of	  N-­‐terminal	  acetyla1on?	  
Protein	  stability?	  Protein	  secre'on?	  
Figure	  courtesy	  of	  Kris	  Gevaert	  

=	  pa1ent	  samples	  prepared	  for	  N-­‐terminal	  COFRADIC	  analyses	  (but	  s1ll	  
to	  be	  analyzed)	  (#8	  and	  #9)	  
=	  FFPE	  DNA	  (for	  pa1ent	  III.7.)	  or	  DNA	  from	  blood	  available	  (and	  for	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=	  pa1ent	  samples	  analyzed	  by	  N-­‐terminal	  COFRADIC	  analyses	  (#1	  to	  #5)	  
III.4.	  proband	  hemizygous,	  mutant	  (89323)	  (#1a)	  (#1b)	  
II.2.	  mother	  of	  proband,	  carrier	  (89324)	  (#2)	  
II.A.	  married-­‐in	  father	  of	  proband,	  WT(89325)	  
III.2.	  brother	  of	  proband,	  WT(90526)	  (#3)	  
III.1.	  sister	  of	  proband,	  WT	  (90527)	  (#4)	  
I.2.	  grandmother	  of	  proband,	  carrier	  (90528)	  
I.1.	  married-­‐in	  grandfather	  of	  proband,	  WT(90529)	  (#5)	  
II.7.	  aunt	  of	  proband,	  WT	  (90530)	  (#6)	  
II.3.	  aunt	  of	  proband,	  carrier	  (90531)	  
II.B.	  married-­‐in	  uncle	  of	  proband,	  WT(90532)	  (#8)	  
II.8.	  uncle	  of	  proband,	  WT(90688)	  (#9)	  
II.5.	  aunt	  of	  proband,	  carrier	  with	  deceased	  boy	  (90797)	  (#7)	  
Proteomics	  Analysis	  of	  EBV-­‐transformed	  cell	  lines	  
from	  family	  members	  
N-­‐terminal	  COFRADIC	  
Staes	  A	  et	  al.	  (2011)	  Nat.	  Protoc.	  6,	  1130-­‐1141	  	  
Gevaert	  K	  et	  al.	  (2003)	  Nat.	  Biotechnol.	  21,	  566-­‐569	  
Proteomics	  Strategy	  
With	  Thomas	  Arnesen,	  
Petra	  van	  Damme	  
And	  Kris	  Gevaert	  
Results	  from	  EBV-­‐transformed	  lymphocytes	  
 X-­‐chromosome	  skewing	  assays	  on	  DNA	  from	  blood	  in	  the	  carrier	  
females	  showed	  extreme	  skewing	  in	  all	  carriers.	  Therefore,	  
lymphocytes	  without	  the	  muta1on	  may	  have	  selec1ve	  advantage?	  
Why?	  
	  
 Proteomics	  screens,	  iden1fying	  thus	  far	  ~40	  proteins	  that	  are	  
substan1ally	  hypo-­‐acetylated	  in	  the	  proband’s	  EBV-­‐transformed	  
lymphocytes	  vs.	  all	  other	  members	  of	  family.	  
 Skin	  fibroblasts	  from	  proband	  obtained,	  and	  now	  making	  iPS	  cells,	  
enabling	  other	  studies.	  Access	  to	  other	  1ssues	  possible.	  
 Knockout	  Mouse	  for	  NAA10,	  along	  with	  Knock-­‐in	  for	  Naa10p-­‐S37P,	  
to	  study	  in	  this	  organism.	  
 Morpholino	  knockdown	  of	  NAA10	  in	  zebrafish	  to	  recapitulate	  
phenotype	  in	  zebrafish,	  allowing	  studies	  in	  this	  organism	  as	  well.	  




This	  is	  just	  one	  example	  of	  many	  rare	  Mendelian	  
disorders	  yet	  to	  be	  discovered	  
	  
Long-­‐range	  Plans:	  ~750	  DNA	  samples	  from	  many	  
pedigrees	  with	  357	  genotyped	  at	  CHOP	  thus	  far	  on	  
Illumina	  610K	  arrays	  
Gene'cs	  of	  Complex	  Neuropsychiatric	  Disorders	  	  
is	  MUCH	  harder	  and	  will	  requires	  decades	  of	  
more	  effort	  
Discov	  Med.	  2011	  Jul;12(62):41-­‐55.	  
This	  is	  one	  ADHD	  pedigree	  in	  January	  2010,	  
very	  well	  phenotyped	  for	  four	  members	  
Figure 1. The pedigree structure is shown, with corresponding ID 
numbers. The three subjects in the pedigree affected with ADHD are 
shaded. Only 84060 has the idiopathic hemolytic anemia. The mother, 
father and two sons were sequenced. The two sisters in the family 
declined to participate in the study, thus their phenotype status is 
unknown and marked as “?”. 
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Exome	  Sequencing	  performed	  early	  2010	  
While	  analyzing	  the	  exome	  data,	  research	  subject	  (age	  
~24)	  informs	  me	  that	  he	  recently	  had	  his	  spleen	  
removed!	  
	  
He	  has	  idiopathic	  hemoly'c	  anemia,	  since	  childhood….	  
	  
Although	  I	  am	  not	  his	  physician,	  I	  s'll	  feel	  an	  ethical	  and	  
moral	  obliga'on	  to	  try	  to	  figure	  out	  what	  is	  going	  on….	  
	  
A	  corollary	  of	  this	  is	  that	  I	  am	  ac'vely	  working	  on	  the	  
ethical	  and	  clinical	  aspects	  of	  sequencing	  human	  
genomes.	  
This	  was	  our	  filtering	  pipeline	  
!
Compound	  Heterozygote	  in	  PKLR,	  with	  each	  
muta'on	  inherited	  from	  one	  parent	  
!
Some	  Addi'onal	  Data	  to	  support	  the	  causa'on	  
of	  these	  variants	  for	  idiopathic	  hemoly'c	  
anemia	  
Structural	  Modeling	  is	  also	  consistent	  with	  deleterious	  effects	  of	  these	  muta1ons.	  
Proving	  CAUSALITY	  for	  variants	  is	  cri'cally	  
important	  
 We	  amassed	  evidence	  for	  causality	  of	  the	  PKLR	  
muta1ons.	  
 We	  found	  many	  very	  rare	  variants	  segrega1ng	  with	  ADHD	  
in	  father	  and	  two	  sons,	  which	  we	  replicated	  with	  second	  
round	  of	  exome	  capture	  and	  sequencing	  followed	  by	  
VAAST	  analysis	  on	  same	  samples.	  
 BUT	  we	  have	  not	  yet	  proven	  with	  certainty	  that	  any	  of	  
these	  variants	  cause	  the	  disease,	  either	  by	  themselves,	  or	  
in	  aggregate,	  or	  with	  epista1c	  effects.	  
 Biology	  experiments	  and	  case-­‐control	  genotyping	  must	  be	  
performed	  to	  further	  bolster	  causality.	  	  
	  
And	  there	  are	  so	  many	  more	  intriguing	  psychiatric	  







 Male,	  age	  55	  currently.	  
 Psycho1c	  break	  at	  age	  20	  with	  bipolar	  features.	  
 Evolu1on	  into	  schizoaffec1ve	  disorder	  over	  next	  25	  years.	  
 Also	  with	  severe	  obsessive	  compulsive	  disorder	  and	  severe	  ToureMe	  Syndrome	  
 At	  least	  two	  very	  severe	  suicide	  aMempts	  at	  age	  22,	  including	  throwing	  self	  
under	  a	  truck	  one	  1me	  and	  then	  driving	  head-­‐on	  into	  another	  car	  (with	  death	  
of	  two	  passengers	  in	  other	  car,	  found	  not	  guilty	  by	  reason	  of	  insanity).	  
 Extensive	  medica1on	  trials	  over	  many	  years,	  along	  with	  anterior	  capsulotomy	  
with	  very	  liMle	  effect	  for	  the	  OCD.	  
	  
 Current	  meds:	  
	  	  	  	  	  	  	  	  	  Klonopin	  	  
	  Nico1namide	  

























	  Age	  54	  
	  	  	  	  	  	  	  	  	  	  Age	  25	  	  	  	  	  	  	  	  	  	  	  Age	  24	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Age	  19	  
	   	   	   	   	   	   	  	  	  	  	  	  	  prodromal,	  likely	  bipolar	  
Collected	  35	  DNA	  samples	  from	  the	  extended	  family,	  due	  to	  very	  large	  excess	  of	  
major	  depression,	  	  bipolar,	  ToureMe	  and	  OCD.	  
Expanding	  the	  Pedigree	  –K8101	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12	  UNAFFECTED	  with	  
1cs,	  OCD	  or	  ADHD	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We	  have	  now	  sequenced	  15	  exomes	  with	  44MB	  
Agilent	  capture	  kit	  and	  sequenced	  to	  a[ain	  goal	  
of	  >80%	  of	  target	  region	  at	  >20	  reads	  per	  bp	  
Exome Capture Statistics K24510-84060 K24510-92157-a K24510-84615 K24510-88962 
Target region (bp) 46,401,121  46,401,121  46,401,121  46,257,379  
Raw reads 138,779,950  161,898,170  156,985,870  104,423,704  
Raw data yield (Mb) 12,490  14,571  14,129  9,398  
Reads mapped to genome 110,160,277  135,603,094  135,087,576  83,942,646  
Reads mapped to target region 68,042,793  84,379,239  80,347,146  61,207,116  
Data mapped to target region (Mb) 5,337.69  6,647.18  6,280.01  4,614.47  
Mean depth of target region 115.03 143.25 135.34 99.76 
Coverage of target region (%) 0.9948  0.9947  0.9954  0.9828  
Average read length (bp) 89.91  89.92  89.95  89.75  
Fraction of target covered >=4X 98.17  98.38  98.47  94.25  
Fraction of target covered >=10X 95.18  95.90  95.97  87.90  
Fraction of target covered >=20X 90.12  91.62  91.75  80.70  
Fraction of target covered >=30X 84.98  87.42  87.67  74.69  
Capture specificity (%) 61.52  62.12  59.25  73.16  
Fraction of unique mapped bases on or near target 65.59  65.98  63.69  85.46  
Gender test result M M M F 
The	  current	  state	  of	  Psychiatric	  
Gene'cs	  
“From	  the	  empirical	  evidence	  on	  segrega1on	  paMerns	  within	  
families,	  the	  recurrence	  risk	  to	  rela1ves	  and	  the	  evidence	  from	  
GWAS	  and	  CNV	  analyses,	  it	  appears	  beyond	  doubt	  that	  most	  
psychiatric	  disease	  is	  not	  Mendelian	  in	  the	  sense	  that	  they	  are	  
not	  caused	  solely	  by	  a	  single	  muta1on	  (others	  disagree	  with	  
this	  conclusion28,62).	  That	  is	  not	  to	  say	  that	  Mendelian	  forms	  
cannot	  exist,	  but	  if	  they	  do,	  they	  account	  for	  very	  liMle	  of	  the	  
popula1on	  variance.”	  	  

“A	   primary	   jus1fica1on	   for	   any	   gene1c	   study	   of	   a	   condi1on	   of	  
uncertain	   e1ology	  must	   surely	   be	   to	   shed	   light	   on	   the	   biological	  
causes….	   Focused	   studies	   on	   individual	   cases,	   single	   families	   or	  
gene1cally	  homogeneous	  popula1ons	  do	  not	  currently	  aMract	  the	  
same	   cash	   or	   cachet	   as	   consor1um-­‐based	   GWAS	   studies,	   but	  
promise	   greater	   returns	   in	   terms	   of	   biological	   insight	   and	  
e1ological	  understanding.	  	  
….a	  pathway	  biology	  approach	  …	  provides	  a	  logical	  an1dote	  to	  the	  




Mitchell	  and	  Porteous	  
  Studies	  are	  ongoing	  with	  cell	  lines	  derived	  from	  the	  Ogden	  Syndrome	  
family,	  including	  skin	  fibroblasts	  and	  EBV-­‐transformed	  cell	  lines	  from	  
blood-­‐derived	  monocytes.	  
  Con1nue	  to	  collect	  DNA	  samples	  from	  families	  in	  Utah	  and	  throughout	  
America	  through	  the	  Utah	  Founda1on	  for	  Biomedical	  Research.	  
	  
  Pursue	  the	  gene1c	  basis	  of	  some	  rare	  disorders	  and	  also	  much	  more	  
complex	  neuropsychiatric	  disorders,	  including	  ToureMe	  Syndrome,	  au1sm,	  
OCD,	  ADHD,	  and	  schizophrenia.	  
  Pursue	  the	  biology	  of	  new	  variants	  discovered.	  
  Collect	  and	  test	  DNA	  from	  more	  fetal	  and	  infan1le	  deaths,	  as	  there	  will	  be	  
much	  gene1c	  varia1on	  implicated.	  
Future	  Direc'ons	  
Final	  Thoughts	  
J.	  Rogers	  Hollingsworth:	  “The	  op1mal	  environment	  for	  great	  
innova1on	  and	  scien1fic	  break-­‐through	  is	  characterized	  by	  
	  1.	  a	  maximum	  of	  flexibility	  without	  hindrance	  by	  hierarchical	  
	  structures,	  
	  2.	  a	  maximum	  of	  independence	  of	  researchers	  and	  strong	  
	  encouragement	  for	  risky	  projects,	  and	  
	  3.	  a	  large	  variety	  of	  different	  cultural	  backgrounds	  of	  the	  
	  researchers.“	  
	  	  
J.R.	  Hollingsworth.	  Ins1tu1onalizing	  Excellence	  in	  Biomedical	  
Research.	  In:	  D.H.	  Stapelton,	  ed.	  Crea%ng	  a	  Tradi%on	  of	  
Biomedical	  Research,	  pp.17-­‐63,	  New	  York	  2004.	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